Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446847 · ClinicalTrials.gov registry record · Phase 2
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
A Phase 2 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02446847 is a Phase 2 study that has completed, run by Rockefeller University. The registered enrollment target is 16 participants.
The verdict
NCT02446847, a Phase 2 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of antiretroviral therapy.
Interventions
- DRUG 3BNC117
- OTHER ART Interruption
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-03-11 |
| Est. Completion | 2017-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446847
The ClinicalTrials.gov registry entry for NCT02446847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3BNC117 is the first listed.
NCT02446847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446847 about?
NCT02446847 is a clinical study titled "3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption". This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of antiretroviral therapy.
What is the current status of trial NCT02446847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-03-11. Estimated completion is 2017-03-25.
What interventions are being tested in trial NCT02446847?
The interventions under investigation include: 3BNC117 (DRUG), ART Interruption (OTHER).
Who is sponsoring clinical trial NCT02446847?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.